Brief: Vaxart Announces Last Subject Dosed In Mid-Stage Trial Of Bivalent Norovirus Candidate

Vaxart

06/06/2023 13:58

June 6 (Reuters) - Vaxart Inc  VXRT.O :
    * VAXART ANNOUNCES LAST SUBJECT DOSED IN PHASE 2 TRIAL OF
ITS
BIVALENT NOROVIRUS CANDIDATE, AND ALL SUBJECTS CHALLENGED IN
PHASE 2 CHALLENGE STUDY OF MONOVALENT NOROVIRUS CANDIDATE
    * VAXART INC - NO VACCINE RELATED SERIOUS ADVERSE EVENTS
(SAES)
REPORTED TO DATE
    * VAXART INC - ON TRACK TO REPORT TOPLINE DATA FROM TWO
PHASE 2
NOROVIRUS VACCINE STUDIES OVER NEXT 3 MONTHS
    * VAXART - CONTINUES TO EXPECT TO REPORT TOPLINE DATA FROM
ONGOING
PHASE 2 DOSE-RANGING STUDY OF ITS BIVALENT NOROVIRUS VACCINE
CANDIDATE IN MID-2023
    * VAXART - EXPECTS TO REPORT TOPLINE DATA FROM ONGOING PHASE
2
CHALLENGE STUDY OF CO'S G1.1 MONOVALENT NOROVIRUS VACCINE
CANDIDATE DURING Q3 2023

Source text for Eikon:  ID:nGNX3XgTL4 
Further company coverage:  VXRT.O 

 ((Reuters.Briefs@thomsonreuters.com;))